Drug Trial Radar · NCT04077463
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
701
Actual
Start
Sep 4, 2019
Primary completion
Feb 12, 2027
Study completion Mar 27, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Sep 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to confirm the tolerability of recommended Phase 2 dose (RP2D) of Lazertinib (Phase 1), to determine the tolerability and identify the recommended Phase 2 combination dose of Lazertinib when combined with Amivantamab (JNJ-61186372) (Phase 1b), to characterize the safety and tolerability of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced non-small cell lung cancer (NSCLC) with documented advanced or metastatic epidermal growth factor receptor (EGFR) mutation (Phase 1b expansion cohorts A, B, C, D and E), to estimate the antitumor activity of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced NSCLC with documented advanced or metastatic EGFR mutation (Phase 1b expansion cohorts A, B, C, and D), to validate the biomarker identified in Phase 1b expansion Cohort D as a predictor of antitumor activity of Lazertinib and Amivantamab combination (Cohort E) or Amivantamab monotherapy (Cohort F) in participants with osimertinib-relapsed, chemotherapy-naïve, EGFR Exon19del or L858R mutated NSCLC, to identify the recommended Phase 2 dose (RP2ChD) of Lazertinib when combined with Amivantamab and standard of care chemotherapy and to determine the tolerability of the Lazertinib, Amivantamab, and platinum-doublet chemotherapy (LACP) combination (Phase 1b LACP combination cohort) and to characterize the safety and tolerability of Lazertinib at the RP2ChD and Amivantamab and standard of care chemotherapy in participants with advanced or metastatic EGFR-mutated NSCLC (Phase 1b LACP combination cohort), to assess 2 potential biomarker strategies to identify participants at increased, or decreased, probability of tumor response with JNJ-61186372 and lazertinib combination in participants with EGFR Exon19del or L858R mutated NSCLC progressed on or after osimertinib (Phase 1b expansion Cohort D).
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
LazertinibDrug
Lazertinib will be administered orally.
AmivantamabDrug
Amivantamab will be administered as an intravenous (IV) infusion.
CarboplatinDrug
Carboplatin will be administered as IV infusion.
PemetrexedDrug
Pemetrexed will be administered as IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Dose-Limiting Toxicity (DLT) (Phase 1)Time frame: Until the end of first cycle (21 days for Phase 1)
- Percentage of Participants with Dose-Limiting Toxicity (DLT) (Phase 1b)Time frame: Until the end of first cycle (28 days for Phase 1b)
- Overall Response Rate (ORR) (Phase 1b Expansion Cohorts A-D)Time frame: Up to 2.5 years
- Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability (Phase 1b Expansion Cohorts A-E)Time frame: Up to 2.5 years
- Percentage of Participants with DLT (Phase 1b combination Lazertinib, Amivantamab, Platinum-doublet chemotherapy [LACP])Time frame: Until the end of first cycle (21 days for Phase 1b combination LACP)
- Number of Participants with AEs as a Measure of Safety and Tolerability (Phase 1b combination LACP)Time frame: Up to 2.5 years
- Overall Response Rate (ORR) per RECIST version 1.1 (v1.1) with NGS Analysis of Circulating Tumor ctDNA, IHC Analysis of EGFR and MET Expression (Phase 1b Expansion Cohort D)Time frame: Up to 2.5 years
- ORR Among Participants with MET3+ Staining on Greater Than or Equal to (>=)25 Percent (%) of Tumor Cells (Phase 1b Expansion Cohorts E and F)Time frame: Up to 2.5 years
- Duration of Response (DOR) Among Participants with MET3+ Staining on >=25% of Tumor Cells (Phase 1b Expansion Cohorts E and F)Time frame: Up to 2.5 years
- Clinical Benefit Rate (CBR) Among Participants with MET3+ Staining on >=25% of Tumor Cells (Phase 1b Expansion Cohorts E and F)Time frame: Up to 2.5 years
Locations
78 sites in 10 countries. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center
Los Angeles, California
University of California Irvine
Orange, California
UCSF Helen Diller Comprehensive
San Francisco, California
Stanford University Medical Center
Stanford, California
Cedars Sinai Medical Center
West Hollywood, California
H. Lee Moffitt Cancer & Research Institute
Tampa, Florida
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Boston University Medical Center
Boston, Massachusetts
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Washington University School Of Medicine
St Louis, Missouri
Langone Health at NYC University, NYU School of Medicine
New York, New York
Columbia University Medical Center
New York, New York
Providence Portland Medical Center
Portland, Oregon
University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania
Huntsman Cancer Institute
Salt Lake City, Utah
Virginia Cancer Specialists
Fairfax, Virginia
University of Washington
Seattle, Washington
Beijing Cancer Hospital
Beijing, China
The First Bethune Hospital of Jilin University
Changchun, China
Hunan Cancer hospital
Changsha, China
West China School of Medicine/West China Hospital, Sichuan University
Chengdu, China
Chongqing University Cancer Hospital
Chongqing, China
The Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Central Hospital of Jinan
Jinan, China
The Second Affiliated Hospital of Kunming Medical University
Kunming, China
Shanghai Chest Hospital
Shanghai, China
Shengjing Hospital Of China Medical University
Shenyang, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Union Hospital Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
The First Affiliated Hospital of Xian Jiaotong University
Xi'an, China
Institut Bergonie
Bordeaux, France
Centre Leon Berard
Lyon, France
CHU de la Timone
Marseille, France
Institut Curie
Paris, France
CHU De Poitiers
Poitiers, France
HIA Begin
Saint-Mandé, France
Institut Gustave Roussy
Villejuif, France
Evangelische Lungenklinik Berlin
Berlin, Germany
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.